Publication:
Adverse drug reactions due to drug- drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method

Simple item page
dc.contributor.authorOKUYAN, BETÜL
dc.contributor.authorsYucel, Emre; Sancar, Mesut; Yucel, Aylin; Okuyan, Betul
dc.date.accessioned2022-03-10T15:25:22Z
dc.date.available2022-03-10T15:25:22Z
dc.date.issued2016
dc.description.abstractIntroduction: Many systematic reviews resulted in claims on drug-drug interactions (DDIs) with proton pump inhibitors (PPIs). Such a large number begs for consensus on the clinical significance of findings.Areas covered: We critically evaluated the safety of PPI use with respect to DDIs with a meta-review of systematic reviews published between 1978 and 2015. We assessed the evidence by their reliability, repeatability, transparency, and objectivity according to the Assessment of Multiple Systematic Reviews (AMSTAR) criteria.Expert opinion: Clinicians must assess risks for each PPI for certain comorbid conditions. DDIs don't substantiate class effect for PPIs; each PPI could induce unique DDIs. Concomitant use of PPIs with thienopyridines (e.g. clopidogrel) could be justified in patients without strong affinity to cytochrome CYP2C19 and with high risk of bleeding (e.g. patients with prior upper gastrointestinal bleeding, Helicobacter pylori infection, advanced age, steroid treatment, and nonsteroidal anti-inflammatory drug use). DDIs could occur in an AIDS subpopulation treated with highly active antiretroviral therapy (HAART). DDIs exist for cancer patients undergoing targeted therapy. Hypomagnesemia could increase in the setting of advanced age and polypharmacy. Omeprazole poses high risks owing to its pharmacokinetic DDI profile. Future systematic reviews should incorporate these additional risks for better clinical guidance
dc.identifier.doi10.1517/14740338.2016.1128413
dc.identifier.eissn1744-764X
dc.identifier.issn1474-0338
dc.identifier.pubmed26635063
dc.identifier.urihttps://hdl.handle.net/11424/220219
dc.identifier.wosWOS:000370390200001
dc.language.isoeng
dc.publisherTAYLOR & FRANCIS LTD
dc.relation.ispartofEXPERT OPINION ON DRUG SAFETY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAdverse drug reactions
dc.subjectAssessment of Multiple Systematic Reviews
dc.subjectdrug-drug interactions
dc.subjectproton pump inhibitors
dc.subjectmeta-review
dc.subjectsystematic review
dc.subjectAMSTAR
dc.subjectPPI
dc.subjectDDI
dc.subjectADR
dc.subjectPATIENTS RECEIVING CLOPIDOGREL
dc.subjectCOATED MYCOPHENOLATE SODIUM
dc.subjectMETHODOLOGICAL QUALITY
dc.subjectMETFORMIN PHARMACOKINETICS
dc.subjectPOTENTIAL INTERACTIONS
dc.subjectINTERACTION PROFILES
dc.subjectMEASUREMENT TOOL
dc.subjectACID
dc.subjectLANSOPRAZOLE
dc.subjectOMEPRAZOLE
dc.titleAdverse drug reactions due to drug- drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method
dc.typereview
dspace.entity.typePublication
local.avesis.idb071ea96-47f9-4170-bbeb-13d798500455
local.import.packageSS5
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages14
local.journal.quartileQ1
oaire.citation.endPage236
oaire.citation.issue2
oaire.citation.startPage223
oaire.citation.titleEXPERT OPINION ON DRUG SAFETY
oaire.citation.volume15
relation.isAuthorOfPublicationf6e7969a-ea61-403f-8772-1a8478556223
relation.isAuthorOfPublication.latestForDiscoveryf6e7969a-ea61-403f-8772-1a8478556223

Files

Collections

Research Outputs